GT Biopharma, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 87/100
What the filing says
GT Biopharma, Inc. (market cap ~$8.6M) issued 8,277.778 shares of Series M 10% Convertible Preferred Stock on September 14, 2026, at $1,000 stated value per share ($8.3M aggregate, $7.45M cash raised). Securities include conversion rights at $6.10/share into common stock, warrants exercisable at $6.10 for 5 years, and vesting warrants. Holders entitled to 10% annual dividends (12% after Sept 2027) and anti-dilution protection. Company granted up to $30M greenshoe rights. Registration of conversion shares required within 90 days or liquidated damages accrue.
Why this rating
Raises ~86% of company market cap; material capital infusion. Dilutive structure with conversion/warrant overhang and extensive holder protections risks substantial equity dilution if exercised. Transforms funding position but creates significant future obligation.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-24.3% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $12.50 ▲ 32.11% | at our read · unknown $9.46 | +10 min · unknown $8.63 ▼ 8.74% | +30 min · unknown $8.46 ▼ 10.59% | +1 hr · unknown $8.92 ▼ 5.73% | +4 hrs pending |
The stock had already moved -24.30% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.